Table 1.
Ongoing and completed clinical trials of immune checkpoint inhibitor combined with other treatment modalities.
| Trial ID | Intervention | Immune Checkpoint-related Target | Antagonist or agonist | Phase | Outcome |
|---|---|---|---|---|---|
| NCT02667587 | TMZ + Nivolumab + RT | PD1 | Antagonist | 3 | Ongoing |
| NCT02617589 | Nivolumab + TMZ + RT | PD1 | Antagonist | 3 | No sig. difference in median OS Ongoing |
| NCT02017717 | Nivolumab + Bevacizumab + Ipilimumab | CTLA4, PD1 | Antagonist | 3 | Ongoing |
| NCT03347097 | Transgenic TILs | PD1 | Antagonist | 1 | Ongoing |
| NCT04888611 | Camrelizumab + GSC-DCV | PD1 | Antagonist | 2 | Ongoing |
| NCT04583020 | Camrelizumab + radiation + Temozolomide | PD1 | Antagonist | 2 | Ongoing |
| NCT04225039 | INCMGA00012 + INCAGN01876 + SRS | PD1 | Antagonist | 2 | Ongoing |
| NCT04977375 | Pembrolizumab + SRS + Resection | PD1 | Antagonist | 1b/2 | Ongoing |
| NCT03961971 | SRS + MBG453 | PD1 | Antagonist | 1 | Ongoing |
| NCT04656535 | AB122 + AB154 | PD1 | Antagonist | 1 | Ongoing |
| NCT03726515 | CART-EGFRvIII T cells + Pembrolizumab | PD1 | Antagonist | 1 | Completed but not yet published |
| NCT04201873 | Pembrolizumab + ALT-DC vaccine | PD1 | Antagonist | 1 | Ongoing |
| NCT02852655 | MK-3475 | PD1 | Antagonist | 1 | Ongoing |
| NCT04013672 | Pembrolizumab + SurVaxM | PD1 | Antagonist | 2 | Ongoing |
| NCT03743662 | Nivolumab + Bevacizumab + RT | PD1 | Antagonist | 2 | Ongoing |
| NCT02658981 | BMS-986016, Urelumab + Nivolumab | PD1 | Antagonist | 1 | Ongoing |
| NCT04606316 | Nivolumab + Ipilimumab + Surgery | CTLA4, PD1 | Antagonist | 1 | Ongoing |
| NCT03233152 | Nivolumab + Ipilimumab | CLTA4, PD1 | Antagonist | 1 | Ongoing |
| NCT02529072 | Nivolumab until resection (group 1) vs nivolumab + DC vaccine until resection (group 2) | PD1 | Antagonist | 1 | Approx. 7 month improvement in median OS for group 2 |
| NCT02287428 | RT + Personalized NeoAntigen Vax + Pembrolizumab + Temozolomide | PD1 | Antagonist | 1 | Ongoing |
| NCT02335918 | Varlilumab + nivolumab | PD1 | Antagonist | 2 | Ongoing |
| NCT03493932 | Nivolumab + BMS-986016 | PD1 | Antagonist | 1 | Ongoing |
| NCT03899857 | Pembrolizumab | PD1 | Antagonist | 2 | Ongoing |
| NCT02968940 | Avelumab + Hypofractionated RT | PD1 | Antagonist | 2 | Ongoing |
| NCT03491683 | INO-5401 + INO-9012 + Cemiplimab + Temozolomide + RT | PD1 | Antagonist | 2 | Ongoing |
| NCT02798406 | DNX-2401 + Pembrolizumab | PD1 | Antagonist | 2 | Ongoing |
| NCT03718767 | Nivolumab | PD1 | Antagonist | 2 | Ongoing |
| NCT03576612 | AdV-tk + Valacyclovir + RT + TMZ + Nivolumab | PD1 | Antagonist | 1 | Ongoing |
| NCT04429542 | BCA101 + Pembrolizumab | PD1 | Antagonist | 1 | Ongoing |
| NCT03797326 | Pembrolizumab + Lenvatinib | PD1 | Antagonist | 2 | Ongoing |
| NCT04704154 | Regoafenib + Nivolumab | PD1 | Antagonist | 2 | Ongoing |
| NCT02794883 | Durvalumab + Tremelimumab | CTLA4, PD1 | Antagonist | 2 | Ongoing |
| NCT04145115 | Ipilimumab + Nivolumab | CTLA4, PD1 | Antagonist | 2 | Ongoing |
| NCT04003649 | IL13Ralpha2-CRT T cells + Ipilimumab + Nivolumab | CTLA4, PD1 | Antagonist | 1 | Ongoing |
| NCT02311920 | Ipilimumab + Nivolumab + TMZ | CTLA4, PD1 | Antagonist | 1 | Ongoing |
| NCT04323046 | Ipilimumab + Nivolumab | CTLA4, PD1 | Antagonist | 1 | Ongoing |
| NCT04047706 | BMS-986205 + Nivolumab + RT + TMZ | IDO1, PD1 | Antagonist | 1 | Ongoing |
| NCT02052648 | Indoximod + TMZ + Bevacizumab + Stereotactic RT | IDO | Antagonist | 1 | 3.7 mo. increase in median OS |
| NCT04049669 | Indoximod + TMZ + Cyclophosphamide + Etoposide + Lomustine + RT | IDO | Antagonist | 2 | Ongoing |